Verici Dx validated a 29-gene RNA expression immune signature that predicts acute kidney rejection risk before transplantation, independent of donor characteristics. The company said its next-gen sequencing assay, Pre-Transplant Risk Assessment (PTRA), was validated in a clinical study published in Kidney360. Verici previously named the test Clarava and licensed it to Thermo Fisher Scientific, which markets it under the One Lambda brand. The company is positioning pre-transplant prediction as an unmet clinical need versus post-transplant assessments that often rely on recipient signals after the graft is already in place. PTRA measures expression of 29 genes in blood, stratifying patients into high- or low-risk categories for early acute rejection. Verici said it addresses the challenge of predicting immune response using only recipient-derived data collected prior to surgery. If the approach scales in additional validation studies, it could influence allocation planning, monitoring intensity, and trial enrichment strategies for immunosuppression regimens.